Ab immunization of Alzheimer's disease (AD) patients in the AN1792 (Elan Pharmaceuticals) trial caused Ab removal and a decreased density of neurons in the cerebral cortex. As preservation of neurons may be a critical determinant of outcome after Ab immunization, we have assessed the impact of previous Ab immunization on the expression of a range of apoptotic proteins in post-mortem human brain tissue. Cortex from 13 AD patients immunized with AN1792 (iAD) and from 27 nonimmunized AD (cAD) cases was immunolabeled for proapoptotic proteins implicated in AD pathophysiology: phosphorylated c-Jun N-terminal kinase (pJNK), activated caspase3 (a-casp3), phosphorylated GSK3b on tyrosine 216 (GSK3b tyr216 ), p53 and Cdk5/p35. Expression of these proteins was analyzed in relation to immunization status and other clinical data. The antigen load of all of these proapoptotic proteins was significantly lower in iAD than cAD (P < 0.0001). In cAD, significant correlations (P < 0.001) were observed between: Cdk5/p35 and GSK3b tyr216 ; a-casp3 and Ab 42 ; p53 and age at death. In iAD, significant correlations were found between GSK3b tyr216 and a-casp3; both spongiosis and neuritic curvature ratio and Ab 42 ; and Cdk5/p35 and Abantibody level. Although neuronal loss was increased by immunization with AN1792, our present findings suggest downregulation of apoptosis in residual neurons and other cells. 
INTRODUCTION
Alzheimer's disease (AD) is characterized by the accumulation of b-amyloid (Ab) peptide and hyperphosphorylated tau protein, and eventually synaptic and neuronal loss. The pathophysiology of the neuronal death remains unclear and controversial. Neuropathological studies have provided evidence of apoptotic neuronal death compatible with the slow progression of neuronal degeneration (15, 27, 32) , in addition to possible deregulated autophagic activity (3, 14, 16, 24, 44) . Apoptosis is a sequence of programmed events leading to the activation of caspases and cell disintegration (15, 27, 32) , whereas autophagy is an intracellular catabolic process leading to the removal of aggregated proteins within cells (21, 28, 38) . Both autophagy and apoptosis are highly regulated, play critical roles in tissue homeostasis and tend to be upregulated in response to extracellular or intracellular stress and in neurodegenerative diseases (26) .
In AD, both processes have been extensively studied but their contribution to neuronal death remains unclear. Apoptotic cell death in AD may result from an imbalance between proapoptotic and antiapoptotic proteins (15) . The expression of several proapoptotic kinases such as activated GSK3b phosphorylated at tyrosine 216 (GSK3b tyr216 ) (1, 6, 37) , pPKR (6, 7, 10, 29, 33, 34, 36) , pJNK (9, 18, 42, 43) , p53 (8) and activated caspase-3 (a-casp3) (2, 15, 17, 41) is increased in AD brains. In AD, autophagic activity is increased but may be dysfunctional, with failure of substrate clearance reflected by the presence of vacuoles (3, 14, 16, 24, 44) .
Active Ab 42 immunization (AN1792, Elan Pharmaceuticals) in AD patients led to Ab removal (19, 30, 31) associated with a decrease in phosphorylated tau (pTau) (4), long-term downregulation of inflammation (46) , reduction in the number of neurons and reduced neuritic abnormalities (34, 39) . To investigate possible mechanisms underlying the observed neuronal loss after immunotherapy, we have explored the expression of apoptotic and autophagic proteins in the unique cohort of immunized AD patients from the AN1792 trial.
MATERIALS AND METHODS

Case selection
Immunized AD cases
The brains of clinical AD patients enrolled in the initial Elan Pharmaceuticals Ab immunization trial AN1792 (19) were obtained following consent to post-mortem neuropathology. The study received ethical approval from Southampton and South West Hampshire Local Research Ethics Committees (Reference No: LRC 075/03/ w). Thirteen post-mortem brains in which the cause of the dementia was confirmed as AD neuropathologically were included in this study. All patients had received Ab 42 plus adjuvant and had died between 4 and 162 months after the first immunization (mean 72.8 months, median 63 months), with Braak tangle stage V/VI disease, as previously described (34) ( Table 1 ). The post-mortem delay was between 6 h and 48 h (mean 18.5 h; median 6 h). In addition to dementia, the most common clinical diagnoses recorded in the death certificate were bronchopneumonia, cerebrovascular accident and myocardial infarction. Other diagnoses included ruptured aortic aneurysm, pulmonary embolism, carcinoma of the breast, carcinoma of the bronchus and carcinoma of the pancreas. Neurodegenerative pathology was assessed by standard histological methods including hematoxylin and eosin (H&E), Luxol fast blue/cresyl violet and modified Bielschowsky silver impregnation. Selected sections were immunolabeled for Ab, tau, a-synuclein and TDP43 to confirm AD.
Nonimmunized AD cases
Twenty-seven AD cases provided by the South West Dementia Brain Bank (SWDBB, Bristol, UK) were identified and used as a control unimmunized AD cohort (Supporting Information Table 1 ). All nonimmunized AD (cAD) cases had a clinical diagnosis of AD made during life by an experienced clinician, a Mini-Mental State Examination score of <17 prior to death and satisfied post-mortem neuropathological Consensus Criteria for Alzheimer's disease (20) . The post-mortem delay was between 9 h and 110 h (mean 39 h, median 26 h). The immunized and control AD cases were matched as closely as possible for age, gender, duration of dementia and APOE genotype ( 
Immunohistochemistry
Middle temporal gyrus, usually markedly affected by AD pathology, was investigated in this study. Four-mm sections of formalin- n/a n/a mean 39 median 26
Abbreviations: n/a 5 nonapplicable.
?: unknown.
fixed paraffin-embedded tissue from immunized AD cases (iAD) and cAD cases were immunolabeled together in batches to ensure comparability of staining.
Primary antibodies and immunohistochemistry
To evaluate the impact of active AN1792 immunization on apoptotic and autophagic pathways, we explored by immunohistochemistry the expression of the following proapoptotic proteins: GSK3b tyr216 (polyclonal rabbit anti-phosphorylated GSK3b tyr216 , #ab75745, Abcam) (6, 37), neuron-specific activator of cyclindependent kinase 5 with its activator p35 (C-19 polyclonal rabbit anti-Cdk5/p35, #sc-820, Santa Cruz) (12, 42) , phosphorylated cJun N-terminal kinase (monoclonal rabbit anti-pJNK Thr183/ Tyr185, clone 81E11, #4668, Cell Signaling) (18, 45) , p53 (monoclonal mouse anti-p53, clone DO-1, #sc-126, Santa Cruz) (8) and a-casp3 (polyclonal rabbit anti-activated caspase 3 (Asp175), # 9661, Cell Signaling) (15, 40, 41) ; and of the autophagic proteins ATG5 (initial step) (polyclonal rabbit anti-ATG5, #AP1812b, Abgent) and microtubule-associated protein light chain LC3-II (a marker of the final stage reflecting efficient autophagic activity) (polyclonal rabbit anti-LC3-II, #AP1801a, Abgent) (21, 22, 28) . The specificity of the antibodies pJNK (18), GSK3b tyr216 (1) and CDK5/p35 (22) was previously demonstrated. To demonstrate the specificity of the antibodies p53, ATG5 and LC3II, we performed western blot on human brain tissue homogenates. Immunohistochemistry was carried out by a standard method as previously described (1, 4, 5, 19, 31, 34, 46) . Biotinylated secondary antibodies, normal serum and avidin-biotin complex were from Vector Laboratories (Peterborough, UK). Immunodetection was performed using the avidin-biotin-peroxidase complex method (Vectastain Elite ABC, UK) with 3,3 0 -diaminobenzidine (DAB) as chromogen and 0.05% hydrogen peroxide as substrate. All the sections were dehydrated before mounting in DePeX (BDH Laboratory Supplies, UK). Sections from which the primary antibody was omitted were included in each immunohistochemistry run.
Quantification of immunolabeling
Quantification was performed blind to the identity of the cases. Thirty fields of cortical gray matter at objective magnification x20 were acquired for each case from the same anatomical regions in a zigzag sequence along the cortical ribbon to ensure that all cortical layers were represented. Slides were marked by the same neuropathologist to ensure consistency in the location of acquisition of the images. Protein "load" defined as the percentage of the field immunopositive for the marker of interest was determined using ImageJ (developed by W.S. Rasband National Institutes of Health, Bethesda MD, USA, version 1.47 g), as in our previous studies (1, 4, 5, 19, 34, 46) .
Statistical analysis
The normality of distribution of each marker across the cohort was assessed by examination of quantile-quantile plots (not shown). Levels of each marker were compared between cAD and iAD cases in two-sample two-sided t-tests or nonparametric Mann-Whitney U-tests (depending on the normality of the data). In both groups, correlations were analyzed by Pearson's or Spearman's test, depending on the normality of distribution of the markers. We analyzed the correlation between the apoptosis and autophagyassociated markers and (i) indicators of disease severity and neuronal integrity as reported in our previous published studies as follows: Ab 42 load, pTau load, tangles density by image, dystrophic neurites, spongiosis, number neuronal NeuN1 density by image, neuritic curvature ratio assessed by neurofilament immunohistochemistry, phosphorylated (p)PKR (a marker of early neurodegeneration) (5, 19, 34, 46) ; and (ii) available clinical indicators of disease course and antibody response-duration of dementia, survival time after immunization, age at death, mean and peak antibody level. The threshold for statistical significance was set at 5% for intergroup comparisons and 1% for correlations, as determined by use of SPSS 21.0.
RESULTS
The immunolabeling of all of the antigens was neuronal, with additional labeling of glial cells for some proteins as described in Table  2 . Of note, the immunolabeling of activated-caspase 3 was cytoplasmic with the nuclei of the stained neurons morphologically normal, without the karyorrhexis classically associated with apoptosis.
The expression of all apoptotic kinases was significantly lower in iAD than cAD cases: a-casp3 load, P < 0.001; Cdk5/p35 load, P 5 0.013; p53 load, P < 0.001; GSK3b tyr216 load, P < 0.01; and pJNK, P < 0.001 (Figure 1 ). Of the two autophagic markers examined, LC3-II load was significantly lower in iAD than cAD (P < 0.001) while ATG5 load did not differ between the cohorts (P 5 0.130, Figure 1 ).
The expression of apoptotic and autophagic markers was analyzed for correlation with other aspects of AD pathology (Ab42 load, pTau load, dystrophic neurite counts, spongiosis, NeuN1 neurons and curvature ratio) in the same anatomical region and also with a range of clinical parameters (age, gender, age at death, dementia duration, peak antibody, survival time). We did not 
V C 2017 International Society of Neuropathology observe any modification in the distribution of the proteins between both cohorts except for the GSK3b tyr216 , which was detected mainly in granulo-vacular degeneration (GVD) in the iAD group but not in the cAD group. To take account of possible variations in neuronal density, we also assessed the percentage of all neurons that was immunopositive for a-casp3. This confirmed the striking decrease in neuronal expression of a-casp3 in iAD compared with cAD (P < 0.0001, data not shown).
In the cAD group, a-casp3 load correlated positively with Ab42 (r 5 0.561, P 5 0.005), and Cdk5/p35 correlated positively with pGSK3b tyr216 (r 5 0.642, P < 0.001) ( Table 3) . Comparison of present findings with the clinical data revealed positive correlations between p53 and age at death (r 5 0.564, P 5 0.003), and between LC3-II and dementia duration (r 5 0.691, P 5 0.001) ( Table 3) .
Within the iAD cohort, a-casp3 and GSK3b tyr216 correlated positively with severity of spongiosis, a marker of neuropil degeneration (r 5 0.789, P 5 0.004 and r 5 0.761, P 5 0.007, respectively) ( Table 2 ). ATG5 correlated negatively with Ab42 load (r 5 -0.845, P 5 0.001) and positively with the curvature ratio (abnormal tortuosity of neuritic processes) (r 5 0.841, P 5 0.001) ( Table 4) . Cdk5/p35 correlated positively with peak antibody titer (r 5 0.840, P < 0.001) as well as with mean antibody titer (data not shown) ( Table 4) .
No other correlation was observed in either group.
DISCUSSION
Our results suggest that active Ab immunization of AD patients modulates apoptosis and some autophagic cellular signals, causing downregulation of apoptotic proteins and reduction in the final stage of autophagy activity. The decrease of apoptotic protein expression after immunization could have several explanations: (1) downregulation of apoptosis was a consequence of removal of Ab, consistent with several studies implicating Ab-induced apoptosis in neuronal death in AD (6, 8) . (2) The reduction in apoptotic proteins may simply reflect the accelerated loss of damaged neurons after immunotherapy, as previously reported by us (34), potentially leaving "healthier" neurons less affected by AD pathophysiology. However, the small magnitude of neuronal loss after immunotherapy (about 10%) could not be the sole explanation for the substantial decrease in apoptotic protein load (between 65% and 85%), and analysis of the percentage of all neurons that was immunopositive for a-casp3 confirmed the marked reduction in neuronal expression of this antigen in iAD. (3) Immunotherapy may itself downregulate apoptotic proteins. Further studies are needed to clarify the cellular and molecular processes that underlie these findings. The effects of autophagic proteins are less clear-cut. The reduction in LC3II suggests downregulation of the later steps of autophagy, potentially explained by reduced metabolic requirement for autophagy or perhaps an aborted or dysfunctional autophagic process. Restrictions on tissue availability did not allow us to explore this mechanistically. Analysis in animal models may help to clarify the influence of immunotherapy on autophagy.
The correlation between a-casp3 and Ab 42 in the cAD group, is in accordance with previous reports implicating Ab 42 in neuronal apoptosis (6, 15) . The link between Cdk5/p35 with GSK3b tyr216 is also consistent with previous studies implicating these proteins in the pathophysiology of AD, particularly in the phosphorylation of Tau protein (13, 23) .
Strikingly different associations were observed in the immunized cohort. The relationship between a-casp3, GSK3b tyr216 loads and the severity of spongiosis, a marker of neuropil degeneration, strengthen the association between these proapoptotic proteins and the neuronal loss detected after immunization (34) . This may explain the absence of clinical amelioration in these patients (19) . Due to the nature of the post-mortem study, investigating late-stage of the disease and treatment, we cannot exclude the possibility that immunotherapy may have induced an early acute apoptotic phase followed by a more quiescent phase several years after the treatment.
The relationship between p53 expression and age at death in the control Alzheimer's cohort is consistent with the documented association between apoptosis and increasing age (11) . The increase in LC3-II with dementia duration may be part of a prosurvival adaptive response by neurons and glia to minimize neurodegeneration (14) . After immunization, the anti-Ab immune response (mean and peak Ab antibody titer) was strongly associated with Cdk5/p35 expression. Cdk5/p35 signaling is known to promote microglial phagocytosis of fibrillar Ab (25) , and the present data are in keeping with the enhanced Ab clearance by phagocytic microglia in the immunized patients who developed an immune response (19, 35, 46) . However, it should be noted that the highest Cdk5/p35 level in the immunized cohort was much lower than that in the control group, consistent with the downregulation of microglial activation that occurs when Ab has been completely removed (46) . This study has some limitations, inherent in the use of postmortem tissue. As previously reported (1, 4, 5, 19, 31, 34, 46) , the number of placebo immunization cases from which brains could be obtained (n 5 1) was far too low to provide useful data for statistical analysis and thus our study used AD brains from patients who were not included in a protocol of immunotherapy, although they were matched as closely as possible to the immunized cohort. Furthermore, this was a retrospective observational study rather than a prospective experimental study, which limited the range of In summary, in this unique human brain series from the first anti-Ab 42 trial, our results suggest that anti-Ab 42 immunization downregulates the expression of several proapoptotic proteins in the brain. While these changes might be expected to be beneficial, the absence of cognitive benefit suggests that they occur too late in the disease process or that other mechanisms are responsible for the neuronal death. 
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